SCHEMBL6785258

SCHEMBL6785258

COC(=O)c1ccc(C)c(C#CCCCO)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 5/20 0.49
▸ CYP4A11 Q02928 4/20 0.46
▸ CYP4F2 P78329 3/20 0.44
▸ POLB P06746 1/20 0.43
▸ CSF1R P07333 1/20 0.40
▸ CA12 O43570 1/20 0.40
▸ CA1 P00915 1/20 0.40
▸ CA2 P00918 1/20 0.40
▸ CA7 P43166 1/20 0.40
▸ XDH P47989 1/20 0.40
▸ CA9 Q16790 1/20 0.40
▸ CA14 Q9ULX7 1/20 0.40
▸ MAPT P10636 3/20 0.39
▸ GAA P10253 2/20 0.39
▸ NOTUM Q6P988 1/20 0.39
▸ LMNA P02545 1/20 0.39
▸ TDP1 Q9NUW8 1/20 0.39
▸ CYP2C9 P11712 3/20 0.38
▸ NPC1 O15118 1/20 0.38
▸ MGLL Q99685 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6785176 0.89 ALDH1A1 (0.46) ALDH1A1CYP4A11CYP4F2POLBCA12
SCHEMBL25289661 0.85 HDAC11 (0.49) ALDH1A1CYP4A11CYP4F2POLBCA12
SCHEMBL30506566 0.85 HDAC11 (0.49) ALDH1A1CYP4A11CYP4F2POLBCA12
SCHEMBL7204369 0.85 TSHR (0.39) ALDH1A1MAPTGAATDP1CYP2C9
SCHEMBL1314552 0.79 CYP4A11 (0.55) CYP4A11CYP4F2POLBCA12CA1
SCHEMBL31515286 0.77 ALDH1A1 (0.48) ALDH1A1CYP4A11CYP4F2CA12CA1
SCHEMBL16799629 0.77 CYP4A11 (0.55) ALDH1A1CYP4A11CYP4F2POLBCYP2C9
SCHEMBL31753430 0.77 CYP4A11 (0.55) ALDH1A1CYP4A11CYP4F2POLBCYP2C9
SCHEMBL6297936 0.76 ALDH1A1 (0.42) ALDH1A1MAPTTDP1CYP2C9KDM4E
SCHEMBL6705713 0.75 MGLL (0.44) ALDH1A1CA12CA1CA2CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6784184-B2 FOR THERAPY OF RAS- ONCOGENE-DEPENDENT TUMORS, SUCH AS CANCERS OF PANCREAS, COLON, BLADDER, AND THYROID; USEFUL FOR CONTROLLING METASTASIS, SUPPRESSING ANGIOGENESIS, INDUCING APOPTOSIS, AND RAS-ASSOCIATED PROLIFERATIVE DISEASES WYETH HOLDINGS CORPORATION 2004-08-31 — — US disclosed
Send feedback